Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Revista de investigación clínica
versión On-line ISSN 2564-8896versión impresa ISSN 0034-8376
Resumen
ENRIQUEZ-ACEVES, Isabel et al. Standard Treatment with Bevacizumab as Targeted Therapy in Cervical Cancer. Rev. invest. clín. [online]. 2020, vol.72, n.4, pp.213-218. Epub 04-Abr-2021. ISSN 2564-8896. https://doi.org/10.24875/ric.20000061.
Metastatic, recurrent, or persistent disease in cervical cancer has a poor prognosis. Historically, this group of patients has had limited treatment options, even with the best cytotoxic treatments (platinum-based chemotherapy [CT] doublets). Therefore, investigating new medications that help improve the patient’s quality of life and survival has been essential. Angiogenesis has been shown to play a critical role in tumor cell growth and survival. Bevacizumab is a recombinant humanized monoclonal G1 immunoglobulin targeted against vascular endothelial growth factor. The combination of CT and bevacizumab is associated with an increase in overall survival as well as in progression-free survival and response rates.
Palabras llave : Bevacizumab; Cervical; Cancer; Metastatic antiangiogenic.